Core Insights - IDEXX Laboratories, Inc. (IDXX) reported Q2 2025 earnings per share (EPS) of $3.63, reflecting a year-over-year increase of 48.8% and exceeding the Zacks Consensus Estimate by 9.67% [1][8] - The company's quarterly revenues reached $1.11 billion, marking a 10.6% year-over-year growth, driven primarily by the Companion Animal Group (CAG) Diagnostics [2][8] - Following the earnings announcement, IDXX shares experienced a 9.2% increase in pre-market trading [3] Revenue Performance - Q2 revenues increased by 10.6% year over year, with organic growth of 9%, surpassing the Zacks Consensus Estimate by 4.01% [2][8] - CAG Diagnostics' revenues grew by 10.9% on a reported basis and 9.7% organically, contributing significantly to overall revenue growth [4] - The Water segment's revenues rose by 9.1% year over year, while Livestock, Poultry, and Dairy (LPD) revenues increased by 4.8% [4][5] Margin and Profitability - Gross profit increased by 12.2% to $694.7 million, with a gross margin expansion of 92 basis points to 62.6% despite a 7.9% rise in the cost of revenues [6] - Operating profit surged by 541.4% year over year to $373.1 million, with the operating margin expanding by 734 basis points to 33.6% [6] Financial Position - At the end of Q2, IDEXX had cash and cash equivalents of $164.6 million, slightly up from $164 million at the end of Q1 [7] - Total debt decreased to $423.7 million from $449.8 million at the end of the previous quarter [9] 2025 Guidance - IDEXX raised its 2025 revenue outlook to a range of $4.205 billion to $4.280 billion, indicating a growth of 7.7%-9.7% on a reported basis [10] - The company also updated its full-year EPS guidance to a range of $12.40 to $12.76, projecting a growth of 16%-20% [11] Strategic Insights - The company's innovation-driven strategy has led to solid global growth, with record quarterly instrument placements and strong recurring revenues from CAG Diagnostics [12] - The Water segment showed robust organic growth across major regions, while LPD growth was supported by effective commercial execution [13]

Core Insights - Idexx Laboratories (IDXX) reported revenue of $1.11 billion for the quarter ended June 2025, marking a year-over-year increase of 10.6% and exceeding the Zacks Consensus Estimate of $1.07 billion by 4.01% [1] - The company's EPS for the same period was $3.63, up from $2.44 a year ago, representing a surprise of 9.67% compared to the consensus estimate of $3.31 [1] Financial Performance Metrics - Gross Profit - CAG: 62.8% versus the two-analyst average estimate of 62.6% [4] - Gross Profit - Other: 51.5% compared to the 29.6% average estimate based on two analysts [4] - Gross Profit - LPD: 47% versus the two-analyst average estimate of 51.7% [4] - Gross Profit - Water: 69.6% compared to the 69.6% average estimate based on two analysts [4] Revenue Breakdown - Revenue from Companion Animal Group in the United States was $684.5 million, exceeding the $663.1 million average estimate, reflecting an 8.9% year-over-year increase [4] - Revenue from Companion Animal Group International reached $337.95 million, surpassing the $312.95 million estimate, with a 15.1% year-over-year change [4] - Revenue from LPD International was $26 million, compared to the $25.76 million average estimate, representing a 3.2% year-over-year increase [4] - Revenue from Water International was $24.91 million, exceeding the $24.16 million estimate, with an 11.9% year-over-year change [4] - Total revenue from Companion Animal Group (CAG) was $1.02 billion, compared to the $978.21 million estimated, reflecting a 10.9% year-over-year increase [4] - Revenue from Other was $4.25 million, slightly below the $4.41 million estimate, with a 0.1% year-over-year change [4] - Revenue from Livestock and Poultry Diagnostics (LPD) was $31.76 million, compared to the $31.51 million average estimate, representing a 4.8% year-over-year increase [4] - Revenue from Water was $51 million, exceeding the $50.79 million estimate, with a 9.2% year-over-year change [4] Stock Performance - Idexx shares have returned -2.1% over the past month, while the Zacks S&P 500 composite has changed by +0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - IDEXX reported a revenue increase of 11% as reported and 9% organically, with nearly 7.5% organic growth in Companion Animal Group (CAG) Diagnostic recurring revenues [5][6][8] - Operating profit grew by 14% on a comparable basis, with earnings per share (EPS) of $3.63, reflecting a 17% growth on a comparable basis [7][18] - The company increased its full-year revenue outlook by $90 million, projecting a range of $4.205 billion to $4.280 billion, indicating an overall reported revenue growth of 7.7% to 9.7% [7][20] Business Line Data and Key Metrics Changes - CAG revenue increased by 10%, with CAG Diagnostic recurring revenues growing nearly 7.5% organically, supported by a global average net price improvement of approximately 4% [9][10] - Water business revenues increased by 8% organically, while Livestock, Poultry, and Dairy revenues grew by 3% [16] - Global Reference Lab revenues increased by 5% organically, driven by solid volume growth [14] Market Data and Key Metrics Changes - U.S. clinical visits declined by 2.5% in the quarter, impacting CAG Diagnostic recurring revenue growth [10][12] - International regions saw double-digit growth in CAG Diagnostic recurring revenues, with strong performance attributed to IDEXX's execution and volume gains [9][29] - The company noted that U.S. CAG Diagnostic recurring revenues grew at a premium to U.S. clinical visits by approximately 800 basis points [11] Company Strategy and Development Direction - IDEXX is focused on expanding its commercial capabilities and investing in innovation to support its growing portfolio of diagnostic solutions [21][30] - The company plans to expand its commercial presence in three additional international markets and modestly enhance its U.S. commercial team [29][96] - IDEXX aims to leverage its innovative diagnostic products, such as IDEXX CancerDx and InVueDx, to capture long-term growth opportunities in the veterinary diagnostics market [30][35] Management's Comments on Operating Environment and Future Outlook - Management highlighted the resilience of the veterinary market and the ongoing demand for diagnostics despite macroeconomic pressures [41][42] - The company remains optimistic about the adoption of new innovations and expects to see continued growth in diagnostics utilization driven by pet owners' desire for high-quality care [26][27] - Management acknowledged the dynamic nature of the operating environment, including inflationary impacts and clinical visit trends, while expressing confidence in IDEXX's long-term growth potential [42][93] Other Important Information - Free cash flow was reported at $152 million for Q2, with a net income to free cash flow conversion rate of 80% [18] - The company repurchased $329 million of its shares during the second quarter, contributing to a 2.7% year-over-year reduction in diluted shares outstanding [19] Q&A Session Summary Question: Can you elaborate on the InVue uptake and the types of practices seeing traction? - Management noted excellent feedback on InVue, highlighting its workflow benefits and consistent, accurate results, with placements occurring in both independent and corporate practices [45][47][50] Question: What is the trend in consumables agreements and utilization? - Management indicated that consumables usage is tracking well, with independent practices moving quickly to adopt new instruments, while corporate practices tend to have longer lead times [53][55] Question: How are clinical visit trends reflected in guidance? - Management updated clinical visit trends to align with recent performance, expecting a continuation of the 2.5% decline observed [58][59] Question: What is the long-term trajectory for InVue? - Management maintained a long-term placement opportunity of approximately 20,000 for InVue, expressing confidence in the current year's placements [64][66] Question: Can you discuss the investments in the sales force? - Management confirmed investments in both U.S. and international markets to increase commercial density and support the growing portfolio of diagnostic solutions [95][96]

Financial Data and Key Metrics Changes - IDEXX reported a revenue increase of 11% as reported and 9% organically, with nearly 7.5% organic growth in Companion Animal Group (CAG) Diagnostic recurring revenues [4][6][9] - Operating profit grew by 14% on a comparable basis, with earnings per share (EPS) of $3.63, reflecting a 17% increase on a comparable basis [6][18] - The company increased its full-year revenue outlook by $90 million, projecting a range of $4.205 billion to $4.280 billion, indicating an overall reported revenue growth of 7.7% to 9.7% [6][19][20] Business Line Data and Key Metrics Changes - CAG revenue increased by 10%, with CAG Diagnostic recurring revenues growing nearly 7.5% organically, supported by a global average net price improvement of approximately 4% [9][10] - Water business revenues grew by 8% organically, while Livestock, Poultry, and Dairy revenues increased by 3% [15] - Global Reference Lab revenues increased by 5% organically, driven by solid volume growth [14] Market Data and Key Metrics Changes - U.S. clinical visits declined by 2.5% in Q2, reflecting macroeconomic pressures [10][12] - International regions showed double-digit growth in CAG Diagnostic recurring revenues, with a 62% increase in CAG Diagnostic instrument revenues [9][10][14] - The company noted that U.S. organic CAG Diagnostic recurring revenues grew 6% in Q2, supported by solid volume gains [10][12] Company Strategy and Development Direction - IDEXX is focused on expanding its commercial capabilities and investing in innovation to support its growing portfolio of diagnostic solutions [28][29] - The company plans to expand its commercial presence in three additional international markets and modestly enhance its U.S. commercial team [28][95] - IDEXX aims to leverage its innovative diagnostic products, such as CancerDx and InVueDx, to capture long-term growth opportunities in the veterinary diagnostics market [29][34] Management's Comments on Operating Environment and Future Outlook - Management highlighted the resilience of the veterinary market and the ongoing demand for diagnostics despite macroeconomic pressures [40][41] - The company remains optimistic about the adoption of new innovations and expects to see continued growth in diagnostics utilization driven by an aging pet population [25][41] - Management acknowledged the dynamic environment but expressed confidence in IDEXX's ability to navigate challenges and capitalize on growth opportunities [41][42] Other Important Information - Free cash flow was reported at $152 million for Q2, with a trailing twelve-month net income to free cash flow conversion rate of 80% [18] - The company repurchased $329 million of shares in Q2, contributing to a 2.7% year-over-year reduction in diluted shares outstanding [19] - IDEXX plans to host its annual Investor Day on August 14, 2025, to provide further insights into its strategy and performance [42] Q&A Session All Questions and Answers Question: Can you elaborate on the InVue uptake and the types of practices seeing the most traction? - Management noted excellent feedback on InVue, highlighting its workflow benefits and consistent, accurate results, with placements occurring in both existing IDEXX customers and new practices [46][50] Question: Can you discuss the contracts associated with InVue placements and the utilization trends? - Management indicated that consumables usage is tracking well, with independent practices moving quickly to adopt the technology, while corporate practices tend to have longer lead times [54][56] Question: What is reflected in the guidance regarding clinical visit trends? - Management updated clinical visit expectations to align with recent trends, anticipating a continued decline of about 2.5% for the remainder of the year [60][72] Question: How does the long-term launch trajectory of InVue compare to previous products? - Management remains optimistic about InVue's long-term potential, with a five-year placement opportunity of approximately 20,000 units [66] Question: Can you provide insights into the investments being made in the sales force? - Management confirmed that investments are aimed at increasing commercial density in international markets and enhancing U.S. account coverage to support a growing portfolio [95][98] Question: What early feedback has been received regarding CancerDx? - Management reported strong enthusiasm from veterinarians and pet owners, with initial usage primarily aiding diagnosis, and noted that competitive accounts are also adopting the test [100][102]

Shares of IDEXX Laboratories soared more than 10% in premarket trading Monday after the pet health care company reported better-than-expected second-quarter results and raised its 2025 profit and revenue forecasts. https://t.co/p54yMfscM9 ...

Idexx Laboratories (IDXX) came out with quarterly earnings of $3.63 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $2.44 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +9.67%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $2.92 per share when it actually produced earnings of $2.96, delivering a surprise of +1.37%. Ov ...

Q2 2025 Financial Performance - Revenue reached $1,109 million, an 11% reported growth and 9% organic growth[1] - Operating profit was $373 million, representing 34% of revenue[1] - Diluted earnings per share (EPS) grew by 49% to $3.63, with a comparable growth of 17%[1] - CAG (Companion Animal Group) Diagnostics Recurring revenue reported growth of 9% and organic growth of 7%, with a 730 bps reported and 130 bps comparable year-over-year change in basis points[1] Segment Revenue Growth - CAG revenue was $1,022 million, with 11% reported growth and 10% organic growth[1] - Water revenue reached $51 million, showing 9% reported growth and 8% organic growth[1] - LPD (Livestock, Poultry and Dairy) revenue was $32 million, with 5% reported growth and 3% organic growth[1] 2025 Financial Outlook - Revenue is projected to be between $4,205 million and $4,280 million, representing 7.7% to 9.7% reported growth and 7.0% to 9.0% organic growth[6,7] - Operating margin is expected to be 31.3% to 31.6%, with a reported margin expansion of 240 to 270 bps and a comparable margin expansion of 50 to 80 bps[6,7] - EPS is forecasted to be $12.40 to $12.76, indicating 16% to 20% reported growth and 9% to 13% comparable growth[6,7] U S Companion Animal Practice Growth (As of June 30, 2025) - U S companion animal practices experienced a 6.1% year-over-year growth in total practice revenue[9] - Total visits to U S companion animal practices decreased by 3.4% year-over-year[9] - Clinical visits decreased by 2.5%, while non-wellness visits decreased by 2.7% year-over-year[9] - Diagnostic revenue per clinical visit increased by 4.5% year-over-year[14]

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, August 4, 2025— IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. "Our innovation-driven strategy delivered robust global growth in the second quarter," said Jay Mazelsky, President and Chief Executive Officer. "We saw exceptional momentum with IDEXX InVue Dx™ placements, e ...

Core Insights - Idexx Laboratories (IDXX) is expected to report quarterly earnings of $3.31 per share, a 35.7% increase year-over-year, with revenues projected at $1.07 billion, reflecting a 6.3% year-over-year growth [1] Earnings Projections - The consensus EPS estimate for the quarter has been revised upward by 0.7% over the past 30 days, indicating a collective reassessment by analysts [2] - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3] Revenue Estimates - Revenue from the Companion Animal Group (CAG) is forecasted to reach $978.21 million, a 6.1% increase from the previous year [5] - Revenue from Other segments is expected to be $4.41 million, up 3.9% year-over-year [5] - Livestock and poultry diagnostics (LPD) revenue is projected at $31.51 million, reflecting a 4% increase [5] - Water revenue is anticipated to be $50.79 million, indicating an 8.7% year-over-year growth [6] - Revenue from the Companion Animal Group in the United States is estimated at $663.10 million, a 5.5% increase [6] - International revenue from the Companion Animal Group is expected to be $312.95 million, up 6.6% year-over-year [7] - LPD International revenue is projected at $25.76 million, reflecting a 2.2% increase [7] - Water International revenue is expected to reach $24.16 million, indicating an 8.5% year-over-year growth [7] Gross Profit Estimates - Gross Profit for the Companion Animal Group (CAG) is expected to be 62.6%, compared to 61.7% in the same quarter last year [8] - Gross Profit for Other segments is estimated at 29.6%, down from 57.8% year-over-year [8] - Gross Profit for LPD is projected at 51.7%, slightly up from 51.3% in the previous year [8] - Gross Profit for Water is expected to be 69.6%, compared to 68.6% in the same quarter last year [9] Stock Performance - Over the past month, Idexx shares have returned +5.6%, outperforming the Zacks S&P 500 composite's +3.4% change [9] - Based on its Zacks Rank 3 (Hold), IDXX is expected to perform in line with the overall market in the upcoming period [10]

Core Insights - IDEXX Laboratories, Inc. released its 2024 Corporate Responsibility Report, emphasizing its commitment to enhancing the health and well-being of pets, people, and livestock, aligning with its business strategy [1][3] The Care We Advance - IDEXX advanced its innovation strategy in 2024, launching the IDEXX inVue Dx™ Cellular Analyzer and eight additional new products and services [4] - The company revolutionized cancer care with the launch of IDEXX Cancer Dx™ testing in North America, focusing on early detection of canine lymphoma and planning to expand testing for other canine cancers over the next three years [4] The People We Support - IDEXX enabled access to care for over 79,000 animals in 2024, contributing to a total of over 704,000 animals since 2022 through global social initiatives [4] - The company provided approximately $5.5 million in continuing education credits to veterinary professionals in 2024 [4] - IDEXX logged over 86,000 hours of learning and development, including 23,200 hours dedicated to STEM and AI learning [4] - The company achieved over 25,000 self-reported employee volunteer hours, surpassing its 2025 goal of 15,000 annual volunteer hours [4] - IDEXX reported an 80% engagement rate in its annual employee engagement survey [4] The Planet We Share - IDEXX signed three virtual power purchase agreements to add new clean electricity to the North American and European energy grids [4] - The company increased its commercial fleet's electric and hybrid vehicle composition to over 35% [4] - IDEXX advanced global product circularity by servicing over 34,000 instruments and completing over 90,000 point-of-service upgrades on select IDEXX instruments [4]